Leerink Partners analyst Joseph Schwartz maintained a Hold rating on AN2 Therapeutics, Inc. (ANTX – Research Report) on March 27 and set a price target of $1.00.
Joseph Schwartz has given his Hold rating due to a combination of factors related to AN2 Therapeutics, Inc.’s recent developments and financial performance. The company’s lead asset, epetraborole, is undergoing pivotal trials for non-tuberculous mycobacterial lung disease. While the drug did not demonstrate a significant difference in culture conversion compared to placebo, there were notable improvements in patient-reported outcomes, prompting adjustments in the trial’s statistical analysis plan.
Additionally, AN2 Therapeutics reported a net loss for the quarter, but maintains a solid cash position expected to support operations through 2027. The company’s pipeline includes early-stage trials for Chagas disease and oncology candidates, but these are still in the nascent stages. Given these mixed results and the current financial outlook, Schwartz maintains a Market Perform rating with a price target of $1.
According to TipRanks, Schwartz is a 5-star analyst with an average return of 9.0% and a 41.65% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Insmed, Sarepta Therapeutics, and Travere Therapeutics.